Mesa Laboratories Inc. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2007 (First Quarter of Fiscal 2008). Mesa Laboratories, Inc. manufactures and distributes electronic measurement systems and disposables for niche applications including renal treatment, food processing, medical sterilization, and pharmaceutical processing. The company operates with a direct sales model for domestic DataTrace products and acquired Raven Biological Laboratories, Inc. in May 2006.
Key Financial Metrics
| Metric | Q1 2008 (Ended June 30, 2007) | Q1 2007 (Ended June 30, 2006) |
|---|---|---|
| Net Sales | $4,286,000 | $3,674,000 |
| Gross Profit | $2,901,000 | $2,387,000 |
| Gross Margin | 68% | 65% |
| Net Income | $1,015,000 | $790,000 |
| Diluted EPS | $0.31 | $0.25 |
| Operating Cash Flow | $1,115,000 | $1,160,000 |
| Cash and Equivalents (End of Period) | $3,907,000 | $3,695,000 |
| Total Debt | $0 | $0 |
| Current Ratio | 9:1 | 10:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% ($612,000) year-over-year. This was driven by the inclusion of five additional weeks of sales from the Raven Biological Laboratories acquisition and a 9% increase in existing medical product sales.
- Profitability: Net income rose 28% to $1.015 million. Gross margin improved to 68% from 65%, attributed to higher sales volumes, improved shipping cost recovery, and favorable product mix shifts toward higher-margin DataTrace logging products.
- Expense Management: Selling, General, and Administrative (SG&A) expenses increased to $1.294 million from $1.069 million, primarily due to the additional five weeks of Raven operations. Research and Development expenses decreased to $94,000 from $123,000.
- Balance Sheet: Inventory increased to $3.737 million from $3.297 million. Accounts Receivable decreased to $3.389 million from $3.827 million, though Days Sales Outstanding increased to 73 days from 60 days.
Outlook, Commentary, and Risks
- Management Commentary: Management attributes improved sales and profitability trends to the Raven acquisition. They expect key financial ratios (such as inventory turns and receivables days) to improve as the fiscal year progresses. The company is executing a strategy to increase internally developed products, specifically within the DataTrace family.
- Capital Allocation: The company maintains a surplus cash flow strategy. It continues a share repurchase program (up to 300,000 shares authorized) and paid a quarterly dividend of $0.08 per share. No debt or lines of credit are currently maintained.
- Risks and Contingencies: Key risks include competition in data logging, kidney dialysis, and biological indicator markets; general economic conditions; and the potential discontinuance of dialyzer reuse practices. Management noted potential internal control weaknesses related to the limited size of the accounting staff, which may affect the ability to properly segment accounting duties.
Investor Verification Checklist
- Verify the sustainability of the 68% gross margin, noting the impact of temporary labor market savings and shipping cost recoveries.
- Monitor the trend in Days Sales Outstanding (73 days), which has increased significantly from 60 days in the prior year.
- Confirm the progress of the internal product development strategy for the DataTrace family to offset reliance on the Raven acquisition for growth.
- Review the status of the share repurchase program, noting 215,999 shares remaining to be purchased under the plan as of June 30, 2007.
- Assess the impact of the transition to a direct sales model for domestic DataTrace products on future selling expenses and revenue stability.